Merck & Co.
AWARDS
NEWS
It was a particularly busy week in clinical trial news, largely because of the American Society of Hematology Annual Meeting. Here’s a look.
Study will evaluate the safety and efficacy of the combination of iTeos’ EOS100850 and Merck’s KEYTRUDA® (pembrolizumab)
Similar to the Biotech Bay list, BioSpace takes a look at the top 10 2019 Life Sciences Ideal Employer Report’s for Genetown.
To help kick off the holiday season, BioSpace gave this Christmas classic a unique biopharma spin.
Merck snapped up the company to gain ArQule’s lead investigational candidate, ARQ 531, a novel, oral Bruton’s tyrosine kinase inhibitor currently in a Phase II dose-expansion study for the treatment of B-cell malignancies.
According to PhRMA, there are 264 vaccines in development to prevent and treat diseases. These include infectious diseases (137), cancer (101), allergies (10), autoimmune disease (8) and Alzheimer’s disease (4).
JOBS
IN THE PRESS